Scientists have successfully engineered the most complicated human cell lines ever, indicating that our genomes are more tolerant to significant structural alterations than previously assumed.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Cathie Wood's ARK ETFs published their daily trades for Friday, January 31st, 2025, with a notable emphasis on the biotech sector. Leading the charge in purchases was CRISPR Therapeutics AG ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

Mice with two fathers have been born — and have survived to adulthood — following a complex set of experiments by a team in China.

One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high hopes and ...

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.

The Exa-cel gene therapy treatment is at the forefront of medical technology. It takes the person’s DNA and “edits” out the faulty sickle gene. It’s expensive, too. According to the manufacturer, ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.